Abstract:Breast cancer is the most commonly diagnosed cancer in women globally (1). The estimated numbers of breast cancer cases account for 32% of all new diagnoses for women in the United States in 2024 (2). Radiotherapy is an important component of breast cancer therapy. Adjuvant radiotherapy is the standard of care for patients receiving breast-conserving surgery, which can significantly reduce locoregional recurrence and the breast cancer death rate (3). Regional node radiotherapy in early breast cancer patients significantly reduced breast cancer mortality and all-cause mortality in trials done in recent years (4). However, the development of radioresistance remains a major challenge in improving outcomes for breast cancer patients who receive radiotherapy (5). This research topic aims to explore the mechanisms of radioresistance and find promising predictive and therapeutic methods for radioresistant breast cancer patients. 8 articles were accepted. Screening of radioresistant breast cancer patients is important for improving the effect of radiotherapy. In this topic, Zhang et al. proposed a novel radiotherapy response classification system based upon molecular profiles for estimating radiosensitivity for individual breast cancer patients and elucidated a methodological advancement for the synergy of radiotherapy with immune checkpoint blockade (ICB). This study classified breast cancer patients to radiotherapy-sensitive and radiotherapy-resistant clusters by quantitative RT-PCR analyses of differentially expressed radiotherapy response-related genes (DERRGs). Then, the Riskscore was proposed to improve patient prognosis. The high Riskscore samples had lower radiotherapeutic response and stronger DNA damage repair as well as poor anticancer immunity. Zheng et al. found that a higher Nottingham prognostic index (NPI) score is an independent risk factor for predicting locoregional recurrence in breast cancer. Two nomogram prediction models related to radioresistance were constructed in this study. Six significant variables were identified for the models, including age, body mass index (BMI), TNM stage, NPI, vascular invasion, and perineural invasion. The nomogram prediction model based on the NPI has undergone internal validation and has been found to have good discrimination and calibration. The two studies highlight the importance of identifying radioresistant breast cancer patients through different clinical variables and special radiotherapy response-related genes.The de-escalation of radiotherapy for selected breast cancer patients is also important for overcoming radioresistance. Because prolonged radiation therapy is more likely to induce secondary radioresistance. Liu et al. conducted a retrospective analysis and found that omitting regional lymph node irradiation may be a safe option in T1-2N1 HER2-overexpressing by breast cancer patients receiving standardized anti-HER2 targeted therapy, particularly in ER-positive or lymph vascular invasion status (LVI)-negative subgroups. The strategies of de-escalated radiotherapy in target volume are also researched for breast cancer patients. The European Society for Radiotherapy and Oncology–Advisory Committee in Radiation Oncology Practice (ESTRO-ACROP) updated a new target volume delineation guideline for postmastectomy radiotherapy after implant-based reconstruction. Park et al. aimed to evaluate the impact on breast complications with the new guideline compared to the conventional guidelines, and found that the new ESTRO-ACROP target volume guideline did not demonstrate significant differences in major or any breast complications compared to the conventional guidelines. It showed a tendency to reduce complication risks by the volume de-escalation of radiotherapy.Tumor volume and radiation dose are predictors of response and can be used to guide the decision-making for patients with radioresistant brain metastases (6). Stereotactic radiosurgery offers a benefit over whole-brain radiation, which is attributed to the reduction of radioresistance and neurotoxicity (7). Li et al. conducted a retrospective analysis to study the role of brain radiotherapy in HER2-positive breast cancer with brain metastases. Because it is considered that with the development of HER2-targeted therapies, brain radiotherapy can be delayed, and stereotactic radiosurgery (SRS) can be used in more patients. The authors concluded that HER2-positive breast cancer with brain metastases still faces significant challenges, particularly those with high intracranial tumor burden, which correlates with poorer outcomes and higher incidence of leptomeningeal metastasis. Larger tumors necessitated more comprehensive treatment approaches, such as whole-brain radiation therapy (WBRT) and SRS. And the target tumor volume and dose of intraoperative radiotherapy (IORT) are also much smaller than conventional radiation. Bhimani et al. demonstrate the suc -Abstract Truncated-

Editorial: Radioresistance in breast cancer

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Promising Stereotactic Body Radiotherapy in NSCLC

Research progress on factors affecting the sensitivity of breast cancer to radiotherapy: a narrative review

Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

Personalizing Locoregional Therapy in Patients With Breast Cancer in 2024: Tailoring Axillary Surgery, Escalating Lymphatic Surgery, and Implementing Evidence-Based Hypofractionated Radiotherapy

Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.

Radioresistance and brain metastases: a review of the literature and applied perspective

DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer

Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases

Early-Stage Breast Cancer Radiotherapy

The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery

Radiotherapy in Preclinical Models of Brain Metastases: A Review and Recommendations for Future Studies

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

Radiotherapy in combination with systemic therapies for brain metastases: current status and progress

Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases

Rbio-06. Stereotactic Radiosurgery Enhances T-Cell Receptor Repertoires And Induces Immunogenicity In Brain Metastasis

Biom-34. Intracranial Management Of Her-2 Overexpression Breast Cancer With Extensive Volume Or Symptomatic Brain Metastases

Comprehensive Analysis of Stereotactic Radiosurgery Outcomes in Triple-Negative Breast Cancer Patients with Brain Metastases: The Influence of Immunotherapy and Prognostic Factors